share_log

君聖泰醫藥-B：HTD1801治療代謝異常性脂肪性肝炎(MASH) IIb期的臨床試驗完成患者入組

HIGHTIDE-B: COMPLETION OF PATIENT ENROLLMENT IN PHASE IIb CLINICAL TRIAL EVALUATING HTD1801 IN MASH

Hong Kong Stock Exchange ·  Apr 3 17:56
Summary by Futu AI
君聖泰醫藥宣布其自主研發的HTD1801治療代謝異常性脂肪性肝炎的IIb期臨床試驗已完成患者入組。該試驗針對伴有2型糖尿病或糖尿病前期的患者，並於2022年12月開始，在美國、香港及中國大陸共入組218名患者。HTD1801獲美國FDA授予快速通道資格，旨在加速治療代謝異常性脂肪性肝炎的藥物開發。君聖泰醫藥專注於開發多功能多靶點療法，目前持有全球知識產權，並推進多項中後期臨床試驗。公司提醒股東及潛在投資者，HTD1801的開發成功與否仍存在不確定性。
君聖泰醫藥宣布其自主研發的HTD1801治療代謝異常性脂肪性肝炎的IIb期臨床試驗已完成患者入組。該試驗針對伴有2型糖尿病或糖尿病前期的患者，並於2022年12月開始，在美國、香港及中國大陸共入組218名患者。HTD1801獲美國FDA授予快速通道資格，旨在加速治療代謝異常性脂肪性肝炎的藥物開發。君聖泰醫藥專注於開發多功能多靶點療法，目前持有全球知識產權，並推進多項中後期臨床試驗。公司提醒股東及潛在投資者，HTD1801的開發成功與否仍存在不確定性。
Jun Shengtai Pharmaceuticals announced that its self-developed HTD1801 Phase IIb clinical trial for the treatment of metabolic abnormal fatty hepatitis has been completed. The trial, in patients with type 2 diabetes or prediabetes, began in December 2022 and enrolled 218 patients in the United States, Hong Kong and Mainland China. HTD1801 has been granted fast-track status by the U.S. FDA to accelerate drug development for the treatment of metabolic abnormal fatty hepatitis. JunShengtai Pharmaceuticals focuses on the development of multifunctional multi-target therapies, currently holds global intellectual property rights and promotes several mid-term and late-stage clinical trials. The Company reminds shareholders and potential investors that there is still uncertainty about the success of HTD1801's development.
Jun Shengtai Pharmaceuticals announced that its self-developed HTD1801 Phase IIb clinical trial for the treatment of metabolic abnormal fatty hepatitis has been completed. The trial, in patients with type 2 diabetes or prediabetes, began in December 2022 and enrolled 218 patients in the United States, Hong Kong and Mainland China. HTD1801 has been granted fast-track status by the U.S. FDA to accelerate drug development for the treatment of metabolic abnormal fatty hepatitis. JunShengtai Pharmaceuticals focuses on the development of multifunctional multi-target therapies, currently holds global intellectual property rights and promotes several mid-term and late-stage clinical trials. The Company reminds shareholders and potential investors that there is still uncertainty about the success of HTD1801's development.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.